C4 Therapeutics, Inc. CCCC 深 沪
已收盘 06-26 16:00:00 美东时间
4.26
-0.140
-3.18%
华盛通- 最 高4.575
- 今 开4.45
- 成交量 2014.44万股
- 最 低 4.14
- 昨 收 4.40
- 总市值 4.71亿
- 52周最高 4.5981
- 市盈率 静 --
- 换手率 18.22%
- 52周最低 1.44
- 委 比 -76.36%
- 总股本 1.11亿
- 历史最高 51.21
- 量 比 6.87
- 振 幅 9.89%
- 历史最低 1.06
- 每 手 1
- 风险率 0.61%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多C4 Therapeutics To Present Further Analysis From Fully Enrolled Phase 1 Trial Of Cemsidomide In Combination With Dexamethasone For Treatment Of RRMM At EHA 2026 Congress
At the 100 µg Recommended Phase 2 Dose (RP2D), Cemsidomide Demonstrated a 53% Overall Response Rate, Including Complete Responses and Minimal Residual Disease (MRD) Negative Status Cemsidomide Was Well Tolerated With Minimal Discontinuations and Dose Reductions Related to Safety or Tolerability Dat...
06-11 19:12
C4 Therapeutics presentation highlights cemsidomide development, targeted protein degrader pipeline strategy
C4 Therapeutics presentation highlights cemsidomide development, targeted protein degrader pipeline strategy C4 Therapeutics outlined plans to advance cemsidomide, an oral IKZF1/3 degrader, as a potential foundational multiple myeloma therapy across lines. Cash runway expected to extend to end of 20
06-11 19:10
C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population
Cemsidomide, a next-generation oral IKZF1/3 degrader, demonstrated a 53% overall response rate (ORR) at the 100 µg recommended Phase 2 dose (RP2D) in patients with relapsed/refractory multiple myeloma (RRMM). The treatment was well-tolerated with minimal discontinuations or dose reductions. Data from the Phase 1 trial support its development as a potential best-in-class therapy, showing durable responses and encouraging activity across subgroups,...
06-11 11:00
美股大行评级 | 瑞杰金融上调美光目标价从530美元升至1100美元；AMD、Arm、戴尔、英特尔等获多家机构上调目标价
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从13.5美元升至14美元；BTIG：维持Jade Biosciences"买入"评级，目标价从39美元升至74美元
06-02 16:25
BMS多发性骨髓瘤III期数据亮眼 C4 Therapeutics受提振大涨
百时美施贵宝日前公布了其在研药物美齐格米德的III期临床试验阳性数据。结果显示，该联合疗法将复发或难治性多发性骨髓瘤患者的疾病进展或死亡风险降低了52%。这...
05-30 03:49
Bristol-Myers multiple myeloma data boosts C4
C4 Therapeutics (CCCC) reached a 52-week high on Friday after a treatment developed by Bristol-Myers Squibb (BMY), similar to the company’s lead candidate, generated impressive survival data in a late...
05-30 02:27
Abercrombie & Fitch Upbeat Q1 Earnings, Joins Digital Turbine, Dycom Industries And Other Big Stocks Moving Higher On Wednesday
Dow Jones up 300 points with gains from Abercrombie & Fitch, Digital Turbine, Dycom Industries, Qfin Holdings, Editas Medicine, and others.
05-27 22:51
C4 Therapeutics to Participate in Upcoming Conferences
C4 Therapeutics, Inc. (C4T) announced that its management will participate in three upcoming conferences. On May 26, 2026, they will join a virtual fireside chat at the TD Cowen Oncology Innovation Summit. On June 3, 2026, they will attend the Jefferies Global Healthcare Conference in New York. Lastly, on June 10, 2026, they will engage in 1x1 meetings at the Goldman Sachs Global Healthcare Conference in Miami. Live webcasts and archived replays ...
05-20 11:00
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
C4 Therapeutics granted 85,480 non-qualified stock options to a new employee as an inducement to join the company. The options, priced at the closing price on May 18, 2026, will vest over four years, with 25% after the first year and the rest in monthly installments thereafter.
05-18 20:01
C4 Therapeutics Realigns Finance Leadership After Officer Departure
C4 Therapeutics ( ($CCCC) ) just unveiled an update. C4 Therapeutics, Inc. anno...
05-16 05:12
